40th Annual J.P. Morgan Healthcare Conference - Syneos Health - Investors
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
40th Annual J.P. Morgan Healthcare Conference Syneos Health January 12, 2022
Forward Looking Statement
Except for historical information, all of the statements, expectations, and assumptions contained in this presentation are forward-looking statements as
that term is defined in the Private Securities Litigation Reform Act of 1995, including Syneos Health, Inc.’s (the “Company”) projected annual adjusted
EBITDA margin expansion, 2022 industry trends, and 2022 strategy. Actual results might differ materially from those explicit or implicit in the forward-
looking statements. Important factors that could cause actual results to differ materially include, but are not limited to: reliance on key personnel; principal
investigators and patients; general and international economic, political, and other risks, including currency and stock market fluctuations and the
uncertain economic environment; the Company's ability to adequately price its contracts and not overrun cost estimates; any adverse effects from the
Company's customer or therapeutic area concentration; the Company's ability to maintain or generate new business awards; the Company's ability to
increase its market share, grow its business, and execute its growth strategies; the Company's backlog not being indicative of future revenues and its
ability to realize the anticipated future revenue reflected in its backlog; fluctuations in the Company’s operating results and effective income tax rate; risks
related to the Company's information systems and cybersecurity; changes and costs of compliance with regulations related to data privacy; risks related to
the United Kingdom’s withdrawal from the European Union; risks related to the Company's transfer pricing policies; failure to perform services in
accordance with contractual requirements, regulatory requirements and ethical considerations; risks relating to litigation and government investigations;
risks associated with the Company's early phase clinical facilities; insurance risk; risks of liability resulting from harm to patients; success of investments in
the Company's customers’ business or drugs; foreign currency exchange rate fluctuations; risks associated with acquired businesses, including the ability
to integrate acquired operations, products, and technologies in our business; risks related to the Company's income tax expense and tax reform; risks
relating to the Company's intellectual property; risks associated with the Company's acquisition strategy; failure to realize the full value of goodwill and
intangible assets; restructuring risk; potential violations of anti-corruption and anti-bribery laws; risks related to the Company's dependence on third
parties; downgrades of the Company's credit ratings; competition in the biopharmaceutical services industry; changes in outsourcing trends; regulatory
risks; trends in the Company's customers’ businesses; the Company's ability to keep pace with rapid technological change; risks related to the Company's
indebtedness; fluctuations in the Company's financial results and stock price; risks associated with business disruptions caused by pandemics such as
COVID-19 (Coronavirus) and other risk factors set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and
other SEC filings, copies of which are available free of charge on the Company's website at investor.syneoshealth.com. The Company assumes no
obligation and does not intend to update these forward-looking statements, except as required by law.
© 2022 Syneos Health®. All rights reserved. Authorized use only. 2SYNH: The Only Fully Integrated Biopharmaceutical Solutions
Organization Purpose Built to Accelerate Customer Success
I N C R E A S I N G LY C O M P L E X E N V I R O N M E N T R E Q U I R E S I N N O VAT I V E S O L U T I O N S
E V O LV I N G M A R K E T D E M A N D S S Y N E O S H E A LT H S O L U T I O N S
Scientific Complexity Product Development Mindset
Regulatory Complexity Integrated Solutions
Rapid Innovation Insights-Driven
SMID Innovation Patient-Centric Approach
DCT and Home Healthcare Va l u e a n d A c c e s s
Market Access Hurdles Fit for Purpose Solutions
Earlier Commercial Consideration Flexible Delivery Models
© 2022 Syneos Health®. All rights reserved. Authorized use only. 3Driving Long-Term Revenue Growth
Executing the Syneos Health Value Creation Plan
• >20% Top 50 clinical ending backlog growth1
• Increasing interest in the value of Commercial applied within Clinical
Penetrate Large Pharma
• Expanding existing relationships and breaking into new accounts
• Beginning to lap growth headwind from one of our largest clinical customers2
• >30% SMID revenue growth year-to-date1 across Clinical and
High-Growth SMID & Emerging Biopharma Commercial, resulting in YTD revenue of nearly $2.0 billion
• Synteract expands support to emerging biopharma
• Gross awards up over 70% year-to-date1
Full-Service Commercial
• Strong adoption among SMID customers
• First Commercial Launch of Syneos One asset in Q3
• Integrating intelligence with Kinetic, our modern customer engagement capability
Innovative Solutions
• Combining technology and home healthcare into Decentralized Solutions
• Full-service Medical Affairs solution, including high-growth RWE services
• StudyKIK enhances patient enrollment and engagement capabilities
M&A Growth Catalysts • RXDataScience brings advanced analytic solutions across the
product development spectrum
1. As of September 30, 2021
2. Represented approximately 300bps of clinical revenue growth pressure year-to-date through September 30, 2021
© 2022 Syneos Health®. All rights reserved. Authorized use only. 4Product Development Model and Mindset Accelerates Success
One-Stop Shop Seamlessly Delivers Insights-Infused Solutions
Clinical Solutions Innovative Commercial Solutions
77% of TTM Revenue1 Solutions 23% of TTM Revenue1
19.8% 9.1%
YTD revenue growth1 Dynamic Assembly YTD revenue growth1
22.3% 24.9%
Ending backlog growth1 Syneos One Ending Deployment Solutions
backlog growth1
1.39x 1.16x
TTM Book-to-Bill1 Medical Affairs TTM Book-to-Bill1
1. As of September 30, 2021
© 2022 Syneos Health®. All rights reserved. Authorized use only. 5Syneos One® Driving Pipeline Growth and Differentiation
Fully Integrated Product Development Solutions Ideal for SMID Market Looking to Retain Asset Control
~$1.1B ~$3.2B
TTM Gross Awards Contribution1 Total Potential Lifetime Value1
C O L L A B O R AT I O N D R I V I N G PIPELINE OF 23+ POTENTIAL ASSET LAUNCHES
I N N O VAT I O N IMPROVES LONG-TERM COMMERCIAL VISIBILITY
12
10
Full Development Operating Model
8
Transformational Design 6
4
End-to-End Predictive Analytics
2
0
2022 2023 2024 2025+
1. As of September 30, 2021
© 2022 Syneos Health®. All rights reserved. Authorized use only. 6Building the Recognized Brand in Medical Affairs Solution Design
High-Value, Underpenetrated Capabilities Unlock New Avenues for Growth
E V O LV I N G R E G U L AT O R Y MARKET LEADERSHIP OPPORTUNITY IN
LANDSCAPE HIGH-GROWTH MARKET
Increasing complexity of
specialized therapies
Increased demand for real
world evidence
Closer HCP and Payer
interactions
Earlier and broader Developing market with the opportunity to grow
stakeholder education double-digits annually
Criticality of value-based Our breadth of capabilities uniquely positions us
data to offer a full-service Medical Affairs solution
© 2022 Syneos Health®. All rights reserved. Authorized use only. 7Dynamic Assembly Accelerates Product Development
Unique Combination of Capabilities and Flexibility Creates a Competitive Advantage
F L E X I B L E F O U N D AT I O N A L T E C H N O L O G Y P L AT F O R M COMBINING BEST OF BREED SOLUTIONS FROM
A D D R E S S E S E V O LV I N G M A R K E T D E M A N D S PA R T N E R S A N D S Y N E O S H E A LT H
Research & Development
Patient
Trial Recruitment Decentralized
Curated Partner Ecosystem
Planning Trials
Patient
Engagement
Syneos Tech-Enabled Services
Ecosystem Data Collection
Intelligence
Dynamic Automation
Real World
Evidence
Assembly® Interoperability Medical
Single-source Affairs
of truth Omnichannel
Engagement
Education &
Campaign Training
Mgt Field Team
Planning &
Commercial KINETICTM
Support
Launch Delivery
© 2022 Syneos Health®. All rights reserved. Authorized use only. 8Driving Efficiency, Effectiveness and a Competitive Advantage
Margin Enhancement Fueling Operational Efficiency and Continued Investment in Innovative Solutions
FY 2022 MARGIN DRIVERS D R I V I N G L O N G - T E R M E F F I C I E N C Y A N D I N N O VAT I O N
Syneos One
Revenue Growth Medical Affairs
Revenue Mix ForwardBound
Decentralized Solutions
Investments M&A
Digital / Analytics / AI
Cell and Gene Therapy
TARGETING 30 – 50 BPS of ANNUAL ADJUSTED EBITDA MARGIN EXPANSION
© 2022 Syneos Health®. All rights reserved. Authorized use only. 9Purpose Built to Accelerate Customer Success
Leading with a Product Development Mindset
EXECUTING CONTINUING TO DELIVERING ON INTRODUCING
AGAINST THE DRIVE OPERATING HIGH-GROWTH OUR UNIQUE,
VALUE CREATION EFFICIENCY AND INNOVATIVE FULL-SERVICE
PLAN TO DRIVE INNOVATION INVESTMENT MEDICAL AFFAIRS
LONG-TERM AREAS SOLUTION
GROWTH
Uniquely Positioned to Deliver Fully Integrated Product Development Solutions
© 2022 Syneos Health®. All rights reserved. Authorized use only. 10Shortening the Distance from Lab to Life®.
You can also read
